How to buy Zai Lab stock (ZLAB)

Zai Lab is a biotechnology business based in the US. Zai Lab shares (ZLAB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $26.22 – a decrease of 0.42% over the previous week. Zai Lab employs 2,175 staff and has a trailing 12-month revenue of around $355.7 million.

Our top picks for where to buy Zai Lab stock

Buy Zai Lab stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Zai Lab stock price (NASDAQ: ZLAB)

Use our graph to track the performance of ZLAB stocks over time.

Zai Lab shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$26.22
52-week range	$13.48 - $36.60
50-day moving average more info button	$28.19
200-day moving average more info button	$20.90
Wall St. target price	$52.39
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.80

Is it a good time to buy Zai Lab stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Zai Lab price performance over time

Historical closes compared with the close of $26.15 from 2024-12-18

1 week (2024-12-13)	-0.68%
1 month (2024-11-20)	-0.30%
3 months (2024-09-20)	19.68%
6 months (2024-06-20)	45.28%

1 year (2023-12-20)	-9.33%
2 years (2022-12-20)	-13.75%
3 years (2021-12-20)	68.2
5 years (2019-12-20)	39

Zai Lab financials

Revenue TTM	$355.7 million
Gross profit TTM	$-145,386,000
Return on assets TTM	-20.83%
Return on equity TTM	-34.98%
Profit margin	-76.14%
Book value	$6.80
Market Capitalization more info button	$2.8 billion

TTM: trailing 12 months

Zai Lab share dividends

We're not expecting Zai Lab to pay a dividend over the next 12 months.

Zai Lab share price volatility

Over the last 12 months, Zai Lab's shares have ranged in value from as little as $13.48 up to $36.6. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zai Lab's is 1.036. This would suggest that Zai Lab's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Zai Lab overview

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO.

Frequently asked questions

What percentage of Zai Lab is owned by insiders or institutions?
Currently 1.506% of Zai Lab shares are held by insiders and 44.515% by institutions. How many people work for Zai Lab?
Latest data suggests 2,175 work at Zai Lab. When does the fiscal year end for Zai Lab?
Zai Lab's fiscal year ends in December. Where is Zai Lab based?
Zai Lab's address is: Jinchuang Plaza, Shanghai, China, 201210 What is Zai Lab's ISIN number?
Zai Lab's international securities identification number is: US98887Q1040 What is Zai Lab's CUSIP number?
Zai Lab's Committee on Uniform Securities Identification Procedures number is: 98887Q104